Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Quali
The purpose of this study is to determine the provider- and practice-level characteristics that influence the impact of implementation strategies guided by practice facilitation in each clinical practice, to test whether the facilitator-driven provider- and practice-level implementation strategies increase provider rec
| Condition(s) | Human Papillomavirus Infection |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The purpose of this study is to determine the provider- and practice-level characteristics that influence the impact of implementation strategies guided by practice facilitation in each clinical practice, to test whether the facilitator-driven provider- and practice-level implementation strategies increase provider recommendations and Human Papilloma Virus (HPV) vaccination rates and to evaluate implementation and future sustainability of the facilitator-driven implementation strategies across nine clinical practice sites |
| Who can participate | Inclusion Criteria: * FQHC's with less than 60% HPV vaccine initiation rate for 11-12 year old adolescents overall at their practice sites * FQHC's that have family medicine and/or pediatric practices * a total adolescent patient population at least 50% Latino * be willing for Health Care Provider (HCP) and staff members to receive education, training, and support; complete standardized measurement, and agree to randomization. * Providers, aged 18 and over, employed at each FQHC (4 staff per practice) * Staff, aged 18 and over, employed at each FQHC (5 staff per practice) * Implementation team members (i.e., administrative designee, health care providers, immunization navigators, and other staff), aged 18 and over, employed at each FQHC (4 members per practice) * Parents (aged 18 and over) |
| Ages | 11 Years to 17 Years |
| Sex | All |
| Lead sponsor | The University of Texas Health Science Center, Houston |
| Locations | Houston, Texas, United States |
| Start date | 2025-03-13 |
| NCT ID | NCT06598475 |
| Official listing | https://clinicaltrials.gov/study/NCT06598475 |